Trial Profile
Phase II Study of Sunitinib as Second-line Treatment in Advanced Biliary Tract Carcinoma: Multicenter, Multinational Study.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Sunitinib (Primary)
- Indications Biliary cancer
- Focus Therapeutic Use
- 13 May 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 22 Jul 2011 Planned end date changed from Feb 2010 to Feb 2012 as reported by ClinicalTrials.gov.
- 22 Jul 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.